Femke Atsma

Femke Atsma

Auto-generated profile, based on publicly available information

Femke Atsma

IQ Health science department, Radboud University Medical Centre, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in International Journal for Quality in Health Care
Verified
Journal Article
Open access
PDF file
FAFemke Atsma
Femke Atsma
GEGlyn Elwyn
Glyn Elwyn
GWGert Westert
Gert Westert
In the past decades, extensive research has been performed on the phenomenon of unwarranted clinical variation in clinical practice. Many studies have been performed on signaling, describing and visualizing clinical variation. We argue that it is time for next steps in practice variation research. In addition to describing and signaling variation patterns, we argue that a better understanding of causes of variation should be gained. Moreover, target points for improving and decreasing clinical variation should be created. Key elements in this new focus should be research on the complex interaction of networks, reflective medicine, patient beliefs and objective criteria for treatment choices. By combining these different concepts, alternative research objectives and new targets for improving and reducing unwarranted variation may be defined. In this perspective, we reflect on these concepts and propose target points for future research.

14 August 2021 in Health Services Research
Verified
Journal Article
Open access
PDF file
IPIrene Papanicolas
Irene Papanicolas
JFJose F. Figueroa
Jose F. Figueroa
ASAndrew J. Schoenfeld
Andrew J. Schoenfeld
KRKristen Riley
Kristen Riley
OAOlukorede Abiona
Olukorede Abiona
AJAshish K. Jha
Ashish K. Jha
Objective: This study explores differences in spending and utilization of health care services for an older person with frailty before and after a hip fracture.Data Sources: We used individual‐level patient data from five care settings.Study Design: We compared utilization and spending of an older person aged older than 65 years for 365 days before and after a hip fracture across 11 countries and five domains of care as follows: acute hospital care, primary care, outpatient specialty care, post–acute rehabilitative care, and outpatient drugs. Utilization and spending were age and sex standardized..Data Collection/Extraction Methods: The data were compiled by the International Collaborative on Costs, Outcomes, and Needs in Care (ICCONIC) across 11 countries as follows: Australia, Canada, England, France, Germany, the Netherlands, New Zealand, Spain, Sweden, Switzerland, and the United States.Principal Findings: The sample ranged from 1859 patients in Spain to 42,849 in France. Mean age ranged from 81.2 in Switzerland to 84.7 in Australia. The majority of patients across countries were female. Relative to other countries, the United States had the lowest inpatient length of stay (11.3), but the highest number of days were spent in post–acute care rehab (100.7) and, on average, had more visits to specialist providers (6.8 per year) than primary care providers (4.0 per year). Across almost all sectors, the United States spent more per person than other countries per unit ($13,622 per hospitalization, $233 per primary care visit, $386 per MD specialist visit). Patients also had high expenditures in the year prior to the hip fracture, mostly concentrated in the inpatient setting.Conclusion: Across 11 high‐income countries, there is substantial variation in health care spending and utilization for an older person with frailty, both before and after a hip fracture. The United States is the most expensive country due to high prices and above average utilization of post–acute rehab care.

30 April 2018 in International Journal for Quality in Health Care
Verified
Journal Article
Open access
PDF file
GWGert P Westert
Gert P Westert
SGStef Groenewoud
Stef Groenewoud
JWJohn E Wennberg
John E Wennberg
CGCatherine Gerard
Catherine Gerard
PDPhil DaSilva
Phil DaSilva
DGDavid C Goodman
David C Goodman
From previous work, we know that medical practice varies widely, and that unwarranted variation signals low value for patients and society. We also know that public reporting helps to create awareness of the need for quality improvement. Despite the availability of rich data, most Western countries have no routine surveillance of the geographic distribution of utilization, costs, and outcomes of healthcare, including trends in variation over time. This paper highlights the role of transparent public reporting as a necessary first step to spark change and reduce unwarranted variation. Two recent examples of public reporting are presented to illustrate possible ways to reduce unwarranted variation and improve care. We conclude by introducing the Value Improvement Cycle, which underscores that reporting is only a necessary first step, and suggests a path toward developing a multi-stakeholder approach to change.

5 August 2021 in Health Services Research
Verified
Journal Article
Open access
PDF file
JFJose F. Figueroa
Jose F. Figueroa
IPIrene Papanicolas
Irene Papanicolas
KRKristen Riley
Kristen Riley
OAOlukorede Abiona
Olukorede Abiona
MAMina Arvin
Mina Arvin
AJAshish K. Jha
Ashish K. Jha
Objective: The objective of this study was to explore cross‐country differences in spending and utilization across different domains of care for a multimorbid persona with heart failure and diabetes.Data Sources: We used individual‐level administrative claims or registry data from inpatient and outpatient health care sectors compiled by the International Collaborative on Costs, Outcomes, and Needs in Care (ICCONIC) across 11 countries: Australia, Canada, England, France, Germany, the Netherlands, New Zealand, Spain, Sweden, Switzerland, and the United States (US).Data Collection/Extraction Methods: Data collected by ICCONIC partners.Study Design: We retrospectively analyzed age–sex standardized utilization and spending of an older person (65–90 years) hospitalized with a heart failure exacerbation and a secondary diagnosis of diabetes across five domains of care: hospital care, primary care, outpatient specialty care, post–acute rehabilitative care, and outpatient drugs.Principal Findings: Sample sizes ranged from n = 1270 in Spain to n = 21,803 in the United States. Mean age (standard deviation [SD]) ranged from 76.2 (5.6) in the Netherlands to 80.3 (6.8) in Sweden. We observed substantial variation in spending and utilization across care settings. On average, England spent $10,956 per person in hospital care while the United States spent $30,877. The United States had a shorter length of stay over the year (18.9 days) compared to France (32.9) and Germany (33.4). The United States spent more days in facility‐based rehabilitative care than other countries. Australia spent $421 per person in primary care, while Spain (Aragon) spent $1557. The United States and Canada had proportionately more visits to specialist providers than primary care providers. Across almost all sectors, the United States spent more than other countries, suggesting higher prices per unit.Conclusion: Across 11 countries, there is substantial variation in health care spending and utilization for a complex multimorbid persona with heart failure and diabetes. Drivers of spending vary across countries, with the United States being the most expensive country due to high prices and higher use of facility‐based rehabilitative care.

11 August 2021 in Health Services Research
Verified
Journal Article
Open access
PDF file
IPIrene Papanicolas
Irene Papanicolas
KRKristen Riley
Kristen Riley
OAOlukorede Abiona
Olukorede Abiona
MAMina Arvin
Mina Arvin
FAFemke Atsma
Femke Atsma
JFJose F. Figueroa
Jose F. Figueroa
Objective: This study explores variations in outcomes of care for two types of patient personas—an older frail person recovering from a hip fracture and a multimorbid older patient with congestive heart failure (CHF) and diabetes.Data Sources: We used individual‐level patient data from 11 health systems.Study Design: We compared inpatient mortality, mortality, and readmission rates at 30, 90, and 365 days. For the hip fracture persona, we also calculated time to surgery. Outcomes were standardized by age and sex.Data Collection/Extraction Methods: Data was compiled by the International Collaborative on Costs, Outcomes and Needs in Care across 11 countries for the years 2016–2017 (or nearest): Australia, Canada, England, France, Germany, the Netherlands, New Zealand, Spain, Sweden, Switzerland, and the United States.Principal Findings: The hip sample across ranged from 1859 patients in Aragon, Spain, to 42,849 in France. Mean age ranged from 81.2 in Switzerland to 84.7 in Australia, and the majority of hip patients across countries were female. The congestive heart failure (CHF) sample ranged from 742 patients in England to 21,803 in the United States. Mean age ranged from 77.2 in the United States to 80.3 in Sweden, and the majority of CHF patients were males. Average in‐hospital mortality across countries was 4.1%. for the hip persona and 6.3% for the CHF persona. At the year mark, the mean mortality across all countries was 25.3% for the hip persona and 32.7% for CHF persona. Across both patient types, England reported the highest mortality at 1 year followed by the United States. Readmission rates for all periods were higher for the CHF persona than the hip persona. At 30 days, the average readmission rate for the hip persona was 13.8% and 27.6% for the CHF persona.Conclusion: Across 11 countries, there are meaningful differences in health system outcomes for two types of patients.

14 March 2019 in Heart
Verified
Journal Article
Closed access
PDF file
KPKarlijn Peffer
Karlijn Peffer
MHMartin Den Heijer
Martin Den Heijer
WKWim L A M de Kort
Wim L A M de Kort
AVAndré L M Verbeek
André L M Verbeek
FAFemke Atsma
Femke Atsma
Objective To investigate whether regular blood donation decreases cardiovascular risk. Methods All 159 934 Dutch whole-blood donors with an active donation career of at least 10 years were categorised into sex-specific donation tertiles based on the number of donations during this 10-year qualification period. Cardiovascular endpoints were based on hospital discharge diagnoses and death certificates from Dutch Hospital Data and Statistics Netherlands and occurring after the 10-year qualification period. Cox regression was used to estimate the age-adjusted and starting year-adjusted hazard rate ratio (HRR). Results Female high-frequency blood donors had a reduced cardiovascular morbidity (HRR=0.91, 95% CI 0.85 to 0.98) compared with low-frequency blood donors. No effect was observed in men (HRR=1.00, 95% CI 0.95 to 1.05). To rule out a residual healthy donor effect (HDE), additional sensitivity analyses using a 5-year qualification period were conducted. The results supported the absence of a residual HDE. Conclusions This study showed a protective effect of long-term, high-frequency blood donation against cardiovascular disease. This effect was only observed in women and not in men.